单克隆抗体MGb2和LAK细胞的协同抗胃癌作用  

The Cytotoxic Effect on Gastric Cancer Synergetically by LAK Cells Together with Antigastric Cancer Monoclonal Antibody

作　　者：毕锋[1] 张学庸[1] 牟震先[1] 吴觉平[1] 樊代明[1] 吴开春[1] 

机构地区：[1]第四军医大学西京医院消化病研究室,西安710032

出　　处：《中国肿瘤生物治疗杂志》1996年第1期42-44,共3页Chinese Journal of Cancer Biotherapy

摘　　要：在LAK细胞对胃癌细胞KATOⅢ的杀伤过程中,加入单克隆抗体MGb2能产生明显协同作用。推测此作用的原理是抗体依赖细胞介导的细胞毒性作用(ADCC)。此作用随着制备LAK细胞时白细胞介素2(IL-2)浓度的增加而增高,与LAK活性呈平行关系;制备LAK细胞时,IL-2的诱导时间既影响LAK活性,也影响相应的ADCC作用。The cytotoxicity against gastric cancer cell line KATO Ⅲ of lymphokine activated killer (LAK) cells produced from human peripheral blood mononuclear cells (PBMC) stimulated by interleukin-2 (IL-2) was observed and compared with that of LAK cells together with antigastric cancer monoclonal antibody (McAb) of MGb2. The killing capacity was found to be increased significantly (about 100%, P< 0. 01)when the antigastric McAb MGb2 was added. The ADCC paralleled the LAK activity. When the concentration of IL-2 was 200U/ml, both the LAK activity and ADCC reached their maximum after four days incubation. Our study demonstrated that the combined use of McAb MGb2 and LAK cell may carry a great promise to improve the theapeutic effect for gastric cancer patient.

关 键 词：单克隆抗体 MGB2 LAK细胞 协同抗癌作用 胃癌 

分 类 号：R979.1[医药卫生—药品] R735.2[医药卫生—药学]